## AVITA MEDICAL COMPLETES ISO QUALITY CERTIFICATION AUDIT

- Receives ISO Re-Certification
- Free to CE Mark all regenerative and respiratory products for sale in the European Union
- Avita Medical featured in Price Waterhouse Cooper's BioForum Quarterly Review.

**21 January 2010. Avita Medical Limited (ASX: AVH**) is pleased to announce that, following a January 2010 Quality Audit by an independent, external auditor of the European Notified Body, the Company has this week received notice of successful audit result with extension to scope to the newly revised and introduced ISO 9001:2008 Quality Management System Certification for Avita's Class III Medical Devices and ISO 13485:2003 Medical Devices Certification.

The audit included examination of Avita's Quality, Manufacturing and Management Systems for its portfolio of medical devices including the Autologous Skin Regenerative product, ReCell Spray-On Skin, as well as the company's respiratory products (Funhaler and Breath-A-Tech).

Successful ISO recertification is critical to the company's goal of global distribution for its products and is an absolute requirement for Avita Medical to CE mark its regenerative and respiratory products for sale within the European Union.

Avita has significantly restructured and streamlined the company's Quality System during the past 12 months; these improvements to the System were noted and the audit included a positive observation that the company has continued and improved performance during 2009.

Mr. William Marshall, Avita Medical's VP Manufacturing and Regulatory said: "We are very pleased with this result. We continue the restructuring and reorganisation of our Quality and Manufacturing operations and processes. The initiatives put in place have yielded greatly improved efficiencies, cost reductions and streamlined manufacture, all of which are significantly improving margins."

In other news, Avita Medical received recent coverage in PricewaterhouseCoopers' quarterly life sciences publication BioForum. We attach a link to the publication, available for download at www.pwc.com.au/bioforum as you may be interested in viewing the entire publication or contemplate subscribing.

The article may be viewed by following the attached link: **PWC BioForum Feature Article: Avita Develops a Growth Culture** [http://www.avitamedical.com/?id=83&ob=1].

- ENDS -

ENQUIRIES:

Dr William Dolphin
Avita Medical Limited
Tel: +44 (0)1223 341 150
wdolphin@avitamedical.com

Rudi Michelson
Monsoon Communications
Tel: +61 (0)3 9620 3333
rudim@monsoon.com.au

## ABOUT AVITA MEDICAL LIMITED

Avita Medical Limited (www.avitamedical.com) is a publicly listed medical technology company (ASX:AVH) that develops and distributes regenerative and tissue-engineered products for the treatment of a wide range of wounds, scars and skin defects. Using proprietary tissue culture, collection, processing and delivery technology, the company is able to provide innovative treatment solutions, derived from the patient's own skin, to enhance healing rates, reduce scar formation and reintroduce pigmentation into the skin.

ReCell® is a stand-alone, rapid cell harvesting device that enables surgeons to treat skin defects using the patient's own cells. The surgeon can prepare a small quantity of cells within 30 minutes on site, replacing the need for skin grafts and obviating the requirement for culturing laboratories. ReCell® has been designed for use in a wide variety of burns, plastic, reconstructive and aesthetic procedures. ReCell® is gaining acceptance in a number of indications including Vitiligo, a common skin pigmentation disease.

ReCell® is patented, CE marked for Europe, TGA registered in Australia, and SFDA cleared in China.